EVs carrying medicine, miRNAs targeting tau pathology, or neurotrophic factors have shown neuroprotective effects, reduced amyloid deposition, improved synaptic plasticity, and cognitive enhancement in AD models [122, 123]. This evidence concerns the gene MAPT and Alzheimer disease.